• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week

    4/1/26 8:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care
    Get the next $PMI alert in real time by email

    TUCSON, Ariz., April 01, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC ("SynCardia"), maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the "Voice of the Patient" event during AZ Tech Week, a program focused on elevating patient perspectives in healthcare innovation hosted by the Arizona Bioindustry Association ("AZBio"), the state's leading organization representing biotechnology and medical device companies. The event will bring together patients, clinicians, and healthcare leaders to discuss the real-world impact of advanced medical technologies.

    Dr. Francisco Arabia, an internationally recognized leader in heart transplantation and mechanical circulatory support, will represent the SynCardia Total Artificial Heart perspective. Dr. Arabia has participated in over 200 SynCardia Total Artificial Heart procedures as an implanting surgeon, proctor, or assisting surgeon at leading transplant and advanced heart failure programs, including Banner University Medical Center Phoenix, the Mayo Clinic in Arizona, Cedars Sinai Medical Center in Los Angeles, and the University of Arizona, among others. He will be joined by Amanda Vaji, Manager of the Mechanical Circulatory Support Program at Banner University Medical Center Phoenix, as well as a patient who will share firsthand experience with SynCardia therapy and recovery from advanced heart failure.

    The broader program will feature patients, clinicians, and healthcare leaders discussing the impact of innovative therapies across a range of diseases.

    The event will take place on Thursday, April 9, 2026, from 1:00 PM to 4:00 PM at the University of Arizona Health Sciences Innovation Forum in Tucson, Arizona. Registration is available at: https://www.azbio.org/events/voice-of-the-patient-az-tech-week/.

    "Advanced heart failure treatment is not only about technology. It is about patients, families, recovery, and quality of life," said Patrick NJ Schnegelsberg, CEO of the Company and of SynCardia. "We are pleased to participate in this event and support a broader conversation that brings patient experience directly into discussions about innovation and care."

    About Arizona Tech Week

    Arizona Tech Week is a statewide innovation conference that brings together founders, investors, researchers, and industry leaders through a series of events hosted across Arizona. The life sciences programming is supported by AZBio. As part of this program, the "Voice of the Patient" event highlights patient perspectives across a range of diseases and medical technologies and brings together clinicians, innovators, and patients to discuss the real-world impact of healthcare innovation. The Company / SynCardia, as member of AZBio, are proud to support the "Voice of the Patient "event as part of AZ Tech Week.

    About Picard Medical and SynCardia

    Picard Medical, Inc. is the parent company of SynCardia Systems, LLC ("SynCardia"), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart, an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

    For additional information about Picard Medical, please visit www.picardmedical.com or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.

    Contact:

    Investors

    Eric Ribner

    Managing Director

    LifeSci Advisors LLC

    [email protected]

    Picard Medical, Inc./SynCardia Systems, LLC

    [email protected]

    General/Media

    Brittany Lanza

    [email protected]



    Primary Logo

    Get the next $PMI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMI
    SEC Filings

    View All

    SEC Form 10-K filed by Picard Medical Inc.

    10-K - Picard Medical, Inc. (0002030617) (Filer)

    3/30/26 6:02:59 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Picard Medical, Inc. (0002030617) (Filer)

    3/27/26 4:15:51 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Picard Medical, Inc. (0002030617) (Filer)

    3/25/26 7:10:31 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Sindex Ssi Lending, Llc claimed ownership of 7,943,585 shares (SEC Form 3)

    3 - Picard Medical, Inc. (0002030617) (Issuer)

    11/13/25 4:15:36 PM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    $PMI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Picard Medical / SynCardia to Participate in Voice of the Patient Event During AZ Tech Week

    TUCSON, Ariz., April 01, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC ("SynCardia"), maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will participate in the "Voice of the Patient" event during AZ Tech Week, a program focused on elevating patient perspectives in healthcare innovation hosted by the Arizona Bioindustry Association ("AZBio"), the state's leading organization representing biotechnology and medical device companies. The event will bring together patients, clinicians, and healthcare leaders to discuss the real-world impact of advanced medical

    4/1/26 8:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical Reports Full Year 2025 Financial Results

    TUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the year ended December 31, 2025. The year reflected a transformational period for the Company highlighted by revenue growth, improved operating performance, and a strengthened balance sheet following the successful completion of the Company public listing and related capital raises. Key Financial Highlights Revenue of $4.9 million, an increase of 12.5 percent compared to 2024Product revenue of $4.7 million represent

    3/25/26 7:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care

    Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology's Annual Scientific Session

    TUCSON, Ariz., March 20, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE:PMI) (the "Company"), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will be presenting a poster consisting of new preclinical data related to its next-generation Emperor Total Artificial Heart at the American College of Cardiology (ACC)'s Annual Scientific Session & Expo (ACC.26) to be held in New Orleans, Louisiana from March 28 to March 30, 2026. Abstract Poster Presentation – ACC.26 Title: THE EMPEROR TOTAL ARTIFICIAL HEART: A FULLY IMPLANTABLE, AUTOREGULATING SOLUTION FOR ADVANCED HEART FAILUREDat

    3/20/26 8:00:00 AM ET
    $PMI
    Medical/Dental Instruments
    Health Care